The General Hospital Corporation

Wisconsin Alumni Research Foundation

Children's Medical Center Corporation

Ross W Cheloha

Thomas J Gardella

Samuel Helmer Gellman

Hidde L Ploegh

Described herein are engineered ligand that binds a cell surface receptor (e.g., GPCR), with improved affinity, potency, and specificity. By conjugating a sub-optimal ligand for a cell surface receptor (e.g., GPCR) to a targeting molecule that binds an epitope (natural or exogenous epitope) in the extracellular portion of the cell surface receptor (e.g., GPCR), the affinity, potency, and/or specificity of the sub-optimal ligand is enhanced.

Engineered ligands and uses thereof

Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent &#x3b2;-amino acid residues in place of a naturally occurring &#x3b1;-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.

Growing community of inventors

Madison, WI, United States of America

Ross W Cheloha